Datroway approved in US: A new era in metastatic breast cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan), a first-in-class TROP2-directed antibody-drug conjugate (ADC) developed by AstraZeneca ... Read More
Hutchmed secures priority review in China for ORPATHYS and TAGRISSO combination therapy
Hutchmed (China) Limited has achieved a significant milestone with the acceptance of its New Drug Application (NDA) by China’s National Medical Products Administration (NMPA) for ... Read More
Game-changer for prostate cancer? AstraZeneca’s Truqap shows remarkable results in pivotal trial
AstraZeneca has announced results from its CAPItello-281 Phase III trial, revealing that Truqap (capivasertib), when combined with abiraterone and androgen deprivation therapy (ADT), significantly improves ... Read More
AstraZeneca to bolster US footprint with multi-billion dollar strategy
In a bold move set to reshape the pharmaceutical landscape, AstraZeneca has announced a substantial $3.5 billion investment aimed at expanding its research and manufacturing ... Read More
AstraZeneca’s breakthrough in lung cancer treatment: Datopotamab deruxtecan achieves promising survival rates
AstraZeneca's datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01 Phase III trial, which focused on patients ... Read More
EC approves AstraZeneca’s Tagrisso with chemotherapy for EGFR-mutated lung cancer
AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy as a ... Read More
AstraZeneca’s CALQUENCE demonstrates enhanced efficacy in mantle cell lymphoma trial
AstraZeneca has announced significant outcomes from the ECHO Phase III trial, highlighting the effectiveness of its drug CALQUENCE (acalabrutinib) when combined with bendamustine and rituximab ... Read More
AstraZeneca secures Fusion Pharmaceuticals in $2.4bn deal to advance cancer treatment
AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating ... Read More
Tempus and AstraZeneca expand collaboration to enhance cancer care with AI
Tempus, a pioneer in artificial intelligence and precision medicine, has announced an expansion of its collaboration with pharmaceutical giant AstraZeneca. This enhanced partnership focuses on ... Read More
AstraZeneca acquisition of Fusion Pharmaceuticals receives shareholder approval
In a significant step towards finalizing the acquisition, Fusion Pharmaceuticals Inc.'s shareholders have overwhelmingly voted in favor of the proposed acquisition by AstraZeneca. During a ... Read More